Das kolorektale Karzinom

Kernaussagen

Risiko und Prävention

• Das kolorektale Karzinom ist eine häufige Erkrankung (Lebenszeitrisiko 6 %), die in der Regel erst in einem fortgeschrittenen Stadium mit Symptomen – am häufigsten Blut im Stuhl – einhergeht.

• Beeinflussbare Risikofaktoren sind Rauchen, Übergewicht, Bewegungsarmut sowie Konsum von Alkohol und rotem Fleisch (Rind, Schwein und Lamm).

• Es stehen effektive Methoden der Früherkennung und im Falle der Koloskopie der Prävention von Karzinomen durch Entfernung von Adenomen zur Verfügung.

Therapie und Nachsorge

• Die Therapie ist abhängig von Stadium und Lokalisation und sollte für jeden Patienten individuell in einem interdisziplinären Tumorboard festgelegt werden.

• Nach kurativer Therapie sollte eine strukturierte Nachsorge der Patienten durchgeführt werden, um auftretende Rezidive zu einem möglichst frühen Zeitpunkt zu diagnostizieren und durch eine erneute Therapie wiederum eine Heilung zu ermöglichen.

• Literatur

• 1 Robert Koch-Institut. Krebs in Deutschland 2007/2008. 8. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin: 2012
• 2 Pox C, Aretz S, Bischoff SC et al. S3-Leitlinie kolorektales Karzinom. Z Gastroenterol 2013; 51: 753-854
• 3 Rothwell PM, Fowkes FG, Belch JF et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41
• 4 Lee SJ, Boscardin WJ, Stijacic-Cenzer I et al. Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom and Denmark. BMJ 2012; 345: e8441
• 5 Hewitson P, Glasziou P, Watson E et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-1549
• 6 Nishihara R, Wu K, Lochhead P et al. Long-term colorectal cancer incidence and mortality after lower endoscopy. N Engl J Med 2013; 369: 1095-1105
• 7 Jasperson KW, Tuohy TM, Neklason DW et al. Hereditary and familial colon cancer. Gastroenterology 2010; 138: 2044-2058
• 8 Al-Sukhni E, Milot L, Fruitman M et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 2212-2223
• 9 Puli SR, Bechtold ML, Reddy JB et al. Can endoscopic ultrasound predict early rectal cancers that can be resected endoscopically? A meta-analysis and systematic review. Dig Dis Sci 2010; 55: 1221-1229
• 10 Ruers TJ, Wiering B, van der Sijp JR et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 2009; 50: 1036-1041
• 11 Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol 2008; 26: 303-312
• 12 Liang Y, Li G, Chen P et al. Laparoscopic versus open colorectal resection for cancer: a meta-analysis of results of randomized controlled trials on recurrence. Eur J Surg Oncol 2008; 34: 1217-1224
• 13 Trastulli S, Cirocchi R, Listorti C et al. Laparoscopic vs open resection for rectal cancer: a meta-analysis of randomized clinical trials. Colorectal Dis 2012; 14: e277-296
• 14 van Gijn W, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2012; 12: 575-582
• 15 Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 2004; 22: 1797-1806
• 16 Twelves C, Scheithauer W, McKendrick J et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012; 23: 1190-1197
• 17 Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116
• 18 Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471
• 19 Yothers G, O’Connell MJ, Allegra CJ et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768-3774
• 20 Gray R, Barnwell J, McConkey C et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029
• 21 Biagi JJ, Raphael MJ, Mackillop WJ et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. A systemic review and meta-analysis. JAMA 2011; 305: 2335-2342
• 22 De Jong MC, Pulitano C, Ribero D et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis. Ann Surg 2009; 250: 440-448
• 23 Arnold D, Seufferlein T. Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut 2010; 59: 838-858
• 24 Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007; 1 p. CD002200